10.01.2025 02:05:14

Zai Lab Partners With MediLink Therapeutics To Develop Novel LRRC15 Antibody-Drug Conjugate

(RTTNews) - Zai Lab Limited (ZLAB) said it has reached a new strategic collaboration and global licensing agreement with MediLink Therapeutics (Suzhou) Co., Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.

In addition, Zai Lab expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025.

Nachrichten zu Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Shmehr Nachrichten

Analysen zu Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Shmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel